博舒替尼

Description

Bosutinib · CAS 380843-75-4 · C26H29Cl2N5O3. UNII 5018V4AEZ0. Melting Point: 131; LogP: 3.34.

Identification

CAS Registry Number	380843-75-4
PubChem CID	5328940
Molecular formula	C26H29Cl2N5O3
IUPAC name	4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
UNII (FDA)	5018V4AEZ0

Computed Descriptors

Molecular Weight	530.4
XLogP3	5.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	9
Exact Mass	529.1647452
Monoisotopic Mass	529.1647452
Topological Polar Surface Area	82.9
Heavy Atom Count	36
Formal Charge	0

Physical & Chemical Properties

Melting Point	131
LogP	3.34

Physical description & handling notes

• A greater likelihood of response and a greater likelihood of safety events were observed with higher bosutinib exposure in clinical studies. The time course of bosutinib pharmacodynamic response has not been fully characterized. At a single oral dose of 500 mg bosutinib with ketoconazole (a strong CYP3A inhibitor), bosutinib does not prolong the QT interval to any clinically relevant extent.

GHS Hazard Classification

Reported hazard statements	H317 (41.7%), H319 (59.7%), H413 (55.6%)

Documented Uses

• Bosutinib is indicated for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia that is newly diagnosed or resistant or intolerant to prior therapy. It is also indicated for the treatment of adult patients with accelerated or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia that is newly diagnosed or resistant or intolerant to prior therapy.
• Bosutinib is a dual kinase inhibitor of both the BCR-ABL and Src tyrosine kinases and is used in the therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Bosutinib therapy is associated with transient elevations in serum aminotransferase and bilirubin levels and rare instances of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors
• Bosutinib is approved to treat:
• • Chronic myelogenous leukemia (CML) that is Philadelphia chromosomepositive. It is used:
• • In adults and children aged 1 year and older with chronic phase CML that is newly diagnosed or cannot be treated with or did not respond to other treatment.

Synonyms

Bosutinib; 380843-75-4; SKI-606; SKI 606; 5018V4AEZ0; SK-606; CHEBI:39112; DTXSID10861568; bosutinibum; uglysycpd2; RefChem:58901; DTXCID40207910; L01XE14; 4-Anilinobenzo(g)quinoline-3-carbonitrile; 700-455-1; 943-866-3

Frequently Asked Questions

What are the CAS number and molecular formula of Bosutinib?

CAS 380843-75-4; molecular formula C26H29Cl2N5O3; molecular weight — g/mol.

What other names is Bosutinib known by?

Bosutinib, 380843-75-4, SKI-606, SKI 606, 5018V4AEZ0, SK-606.

Is Bosutinib classified as hazardous?

Hazard statements reported: H317, H319, H413.

What are the key physical properties of Bosutinib?

Melting Point: 131; LogP: 3.34.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.